Combined finasteride and flutamide therapy in men with advanced prostate cancer

Urology

Volumn 48, Issue 6, 1996, Pages 901-905

  Ornstein, David K ^a   Rao, Ganesh S ^a   Johnson, Brooke ^a   Charlton, Elaine T ^a   Andriole, Gerald L ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Division of Urologic Surgery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; FINASTERIDE; FLUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG MIXTURE; DRUG POTENCY; DRUG SCREENING; DRUG TOLERABILITY; GYNECOMASTIA; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ENZYME INHIBITORS; FINASTERIDE; FLUTAMIDE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0030468455     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00315-9     Document Type: Article

References (25)

1. Peeling WB: Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma. Urology 33(suppl): 45-52, 1989.
2. The Leuprolide Study Group: Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 311: 1281-1286, 1984.
3. Matzkin H, Eber P, Todd B, Van der Zwaag R, and Soloway M: Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer. Cancer 70: 2302-2309, 1992.
4. Miller JI, Ahmann FR, Drach GW, Emerson SS, and Bottaccini MR: The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J Urol 147: 956-961, 1992.
5. Denis L: Prostate cancer: primary hormonal treatment. Cancer 71(suppl): 1050-1058, 1993.
6. Karling P, Hammer M, and Varenhorst E: Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma. J Urol 152: 1170-1173, 1994.
7. Cassileth BR, Soloway MS, Vogelzang PS, Seidmon EJ, Hait HI, and Kennealey GT: Patient's choice of treatment in stage D prostate cancer. Urology 33(suppl): 57-62, 1989.
8. Soloway MS, and Matzkin H: Antiandrogenic agents as monotherapy in advanced prostatic carcinoma. Cancer 71(suppl): 1083-1088, 1994.
9. Chang A, Yeap B, Blum R, Hahn R, Khanna O, Fisher H, Witte R, and Trump D: A double-blind randomized study of primary treatment for stage D2 prostate cancer: diethylstilbestrol (DES) vs flutamide (F) (abstract). Proc Annu Meet Am Soc Clin Oncol 11: abstract 21, 1992.
10. Chodak G, Sharifi R, Kasimis B, Block NL, Macramalla E, and Kennealey GT: Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced prostate carcinoma. Urology 46: 849-855, 1995.
11. McConnell JD: Physiologic basis of endocrine therapy for prostatic cancer. Urol Clin North Am 18: 1-13, 1991.
12. Simard J, Luthy I, Belanger A, and Labrie F: Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues. Mol Cell Endocrinol 44: 261-270, 1986.
13. Rittmaster RS: Finasteride. N Engl J Med 330: 120-125, 1994.
14. Gormley GL, Stoner E, Bruskewitz B, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JV, et al: The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 327: 1185-1191, 1992.
15. Presti JC, Fair WR, Andriole GL, Sogani PC, Seidmon EJ, Ferguson D, Ng J, and Gormley GJ: Multicenter, randomized double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer. J Urol 148: 1201-1204, 1992.
16. Andriole GL, Lieber M, Smith J, Soloway M, Schroeder F, Kadmon D, DeKernion J, Rajfer J, Boake R, Crawford D, et al: Treatment with finasteride following radical prostatectomy for prostate cancer. Urology 45: 491-497, 1995.
17. Fleshner NE, and Trachtenberg J: Sequential androgen blockade: a biological study in the inhibition of prostatic growth. J Urol 148: 1928-1931, 1992.
18. Martel C, Claude T, Couet J, Labrie C, Belanger A, and Labrie F: Blockade of androstenedione-induced stimulation of androgen-sensitive parameters in the rat prostate by combination of flutamide and 4-MA. Mol Cell Endocrinol 91: 43-49, 1993.
19. Petros J, and Andriole GL: Serum PSA after antiandrogen therapy. Urol Clin North Am 20: 749-756, 1993.
20. Arai Y, Yoshiki T, and Yoshida O: Prognostic significance of prostate specific antigen in endocrine treatment for prostate cancer. J Urol 144: 1415-1419, 1990.
21. Zanetti G, Trinchieri A, Del Nero A, Montanari E, Cogni M, Colombo F, Buzzetti V, and Austoni E: Prognostic significance of prostate-specific antigen in endocrine treatment for prostatic carcinoma. Eur Urol 22(suppl): 96-98, 1992.
22. Fleshner NE, and Trachtenberg J: Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects. J Urol 154: 1642-1646, 1995.
23. Brufsky A, Fontaine-Rothe P, Berlane IK, Kaplan I, and Kantoff P: Finasteride and flutamide as potency-sparing androgen ablative therapy for advanced prostate cancer. Proc Am Soc Clin Oncol 15: 252, 1996.
24. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, and Goodman PJ: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321: 419-424, 1989.
25. Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, and Kolvenbag G: A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Urology 45: 745-752, 1995.